MRN ERN Banner
microRNA as Biomarkers and Diagnostic 2016 - 마이크로RNA 바이오마커 및 진단 기술 컨퍼런스 2016 -
2016년 4월 4일 - 2016년 4월 5일
미국 매사추세츠주 케임브리지, Hyatt Regency Cambridge
microRNA as Biomarkers and Diagnostics

최근 연구에 의해 미세 논코딩 RNA인 마이크로RNA는 세포 과정의 주요 제어 요인임이 판명되었으며, 발현 패턴은 진단, 예후 및 치료 반응을 조사하기 위한 바이오마커로서의 가능성을 나타내고 있습니다. Cambridge Healthtech Institute(CHI)가 주최하는 제12회 microRNA as Biomarkers and Diagnostics에서는 질병의 조기 발견, 암의 진행과 치료 반응 감시, 면역 파악 목적으로서의 마이크로RNA 이용에 관한 최신 연구가 소개됩니다. 또한 향후 맞춤형 의료에 미치는 영향, 마이크로RNA 바이오마커의 임상 현장 활용에서의 문제 등도 논의됩니다.

첫째날 | 둘째날


추천 디너 쇼트코스 *

4월 3일(일), 17:00-20:00
(쇼트코스 1) 데이터 정규화 관련 문제와 대책

* 별도 참가 등록 필요


4월 4일(월)

7:00 컨퍼런스 등록 & 커피

8:00 컨퍼런스 디렉터의 환영사


비침습적 진단과 예측을 가능하게 하는 바이오마커로서의 마이크로RNA

8:10 의장 개회사

Ajay Goel, Ph.D., Professor and Director, Center for Gastrointestinal Research, and Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute, Baylor University Medical Center

8:15 결장직장암의 논코딩 RNA 바이오마커

Ajay Goel, Ph.D., Professor and Director, Center for Gastrointestinal Research, and Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute, Baylor University Medical Center

Non-coding RNAs (ncRNAs) are emerging as important regulators of gene expression in cancer. Overexpression of specific non-coding RNAs (including microRNAs, snoRNAs, piRNAs and circular RNAs) has been linked to the stepwise disease progression in colorectal cancer (CRC). Given their cancer-specific pattern of expression, remarkable stability and presence in blood and other body fluids, ncRNAs are considered to be highly promising cancer biomarkers. Accumulating evidence firmly supports the existence of unique 'ncRNA signatures' that can not only facilitate earlier detection of the tumor, but can also assist in predicting disease recurrence and therapeutic outcome to current treatment regimens.

8:45 신장병에 대한 비침습적 마이크로RNA 바이오마커

Vishal S. Vaidya, Ph.D., Associate Professor, Medicine & Environmental Health, Harvard Medical School, Harvard T.H. Chan School of Public Health, Brigham and Women's Hospital

MiRNAs play a critical regulatory role in health and disease. Abundant expression, lower complexity, stability in various detection matrices and amplifiable signals are qualities that make extracellular miRNAs attractive as biomarkers reflecting a variety of pathophysiological conditions. We highlight the transformative potential of miRNAs as mechanistic biomarkers in translational medicine.

9:15 심장병과 기능 장애에서의 혈중 순환 마이크로RNA

Yuri D'Alessandra, Ph.D., Senior Researcher, Immunology and Functional Genomics Unit, Centro Cardiologico Monzino

Circulating microRNAs are emerging as biomarkers of several heart-related diseases. We have conducted studies encompassing many different cardiac maladies and identified specific circulating miRNAs as potential diagnostic markers.

9:45 스폰서 제공 프레젠테이션(연사 모집 중)

10:15 전시회장 휴식시간, 포스터 발표 관람


조직과 바이오유체에 포함되는 마이크로RNA 바이오마커의 식별

10:45 성 특이성, 집단 특이성, 인종 특이성 조절 논코딩 RNA

Isidore Rigoutsos, Ph.D., Professor and Director, Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University

By analyzing human transcriptomes from different people and different tissues, we found two types of short regulatory RNAs that are produced constitutively, and demonstrated that their composition and abundances depend on a person's gender, population and race as well as on tissue, tissue state, and disease subtype. The first type of short RNAs comprises numerous isoforms of mature microRNAs (miRNAs) that arise from virtually every known miRNA precursor. The second type of short RNAs comprises numerous fragments of mature transfer RNAs (tRNAs). We also discovered a novel category of tRNA fragments, the i-tRFs, which are wholly internal to the span of the mature tRNA and contribute much of the observed difference across individuals and tissues. The findings have direct implications for Precision Medicine and our understanding of the mechanisms underlying the onset and progression of disease.

11:15 교아종의 잔존과 치료 반응을 예측하는 마이크로RNA 시그니처의 식별

Sean Lawler, Ph.D., Assistant Professor, Neurosurgery, Brigham & Women's Hospital, Harvard Medical School

11:45 신장 질환에서의 마이크로RNA 시그니처:조직과 요(Urine) 데이터세트의 메타 분석

Christos Argyropoulos, M.D., Ph.D., MS, Assistant Professor, Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine

MicroRNA (miRNA) are negative regulators of gene translation and an emerging biomarker in a wide variety of diseases. Little is known about the ability of miRNA to correctly classify patients with clinically significant renal pathology. We undertook a meta-analysis of miRNA profiles from clinical samples (biopsy or biofluid) in Gene Expression Omnibus. MiRNA profiles from 31 urine samples and 117 biopsy samples were available for analyses. A short signature of 19 miRNAs achieved a superior classification performance for renal pathology (cross-validated AUC 0.96).

12:15 런천 프레젠테이션 또는 개별 점심식사


의약품 개발의 마이크로RNA

1:25 의장 발언

Bing-Hua Jiang, Ph.D., Professor, Pathology, Anatomy and Cell Biology, Thomas Jefferson University

1:30 사구체 장애의 요(Urinary) 중 마이크로RNA 바이오마커 식별

Rounak Nassirpour, Ph.D., Principal Scientist, Biomarkers Laboratory, Drug Safety R&D, Pfizer

Recent studies have reported significant levels of microRNAs in a variety of body fluids, raising the possibility that microRNAs could serve as useful biomarkers. Here we describe urinary microRNA expression alterations in preclinical models of kidney injury. The microRNAs identified may be promising translatable preclinical urinary biomarkers for drug-induced glomerular injury.

2:00 약물 안전성을 높이기 위한 손상 바이오마커로서 기능하는 비침습적 마이크로RNA의 평가

Xi Yang, Ph.D., Research Biologist, Systems Biology, National Center for Toxicological Research, FDA

Drug-induced liver injury is an important regulatory concern and a common reason for drug withdrawal. Acetaminophen (APAP) overdose is a major cause of acute liver failure in the Western world. Sensitive and specific biomarkers are required as diagnosis tools in the clinic and in screening assays during drug development stages. In our recent study, urinary miRNAs' potential as diagnostic biomarkers has been explored.

2:30 마이크로RNA를 이용한 폐종양 아류형으로 예측되는 치료 반응과의 차동 시그널링 파악

Molly A. Taylor, Ph.D., Senior Scientist, AstraZeneca

We have classified three novel subtypes of lung squamous cell carcinoma that each have unique microRNA expression and therapeutic response profiles. Combined analysis of activated pathways and microRNA promoters has identified transcription factors driven by activated pathways that drive differences in microRNA expression. Overall, these microRNAs and transcription factors may function as biomarkers of pathway activation and aid in distinguishing patient subtypes to predict response to therapy.

3:00 전시회장 휴식시간, 포스터 발표 관람

3:30 간질환의 반영으로서의 무세포 순환 마이크로RNA

Steven Lockton, Ph.D., Senior Scientist, microMarkers, Regulus Therapeutics

MicroRNAs are stable in circulation and can be dysregulated with disease. Because microRNA expression is often organ-specific, cell-free circulating microRNA expression often reflects the diseased organ's pathophysiology. To map microRNAs to organs we profiled microRNA expression in mouse tissues. In a transgenic mouse model of hepatocellular carcinoma this serum reflection of liver distress was clearly demonstrated upon inducing HRAS. Similarly, in HCV-infected patients, aberrant serum microRNA expression was restored to a healthy-like state after treatment.

4:00 암의 마이크로RNA와 치료제 내성

Bing-Hua Jiang, Ph.D., Professor, Pathology, Anatomy and Cell Biology, Thomas Jefferson University

We initially demonstrated that PI3K and AKT play an important role in tumor angiogenesis. We found recently that reactive oxygen species (ROS) levels are increased in ovarian, prostate and breast cancer cells; and are involved in activating PI3K/AKT and HER2/HER3 signaling and suppressing several key microRNAs for regulating cancer development, drug resistance, tumor growth and angiogenesis. We found that microRNA dysregulations regulate tumor growth, angiogenesis and drug resistance in several kinds of human cancers. To understand the potential link of ROS and microRNA dysregulations, we showed that ROS can suppress a number of microRNA expression through DNA methylation for inducing some pro-oncogene expression such as HER2/HER3. In addition, we find that miRNA depression is regulated by DNA methylation and transcriptional activation. MiRNA dysregulation is involved in cancer development, autophagy and therapeutic resistance.

4:30 스폰서 제공 프레젠테이션(연사 모집 중)

5:00 전시회장 환영 리셉션, 포스터 발표 관람

6:00 쇼트코스 등록


추천 디너 쇼트코스 *

4월 4일(월), 18:15-21:15
(쇼트코스 2) 마이크로RNA 기반 치료법

* 별도 참가 등록 필요


첫째날 | 둘째날

4월 5일(화)

7:30 브렉퍼스트 라운드테이블 디스커션

Roundtable discussion are interactive, topic-specific discussions hosted by expert moderators and open to all attendees. These session provide a forum for discussing key issues.

  • Topic 1: Targeting of microRNAs for Therapeutics

    Moderator: Amy K. Patick, Ph.D., Principal, Patick Pharmaceutical and Scientific Consulting

  • Topic 2: Next-Generation Sequencing

    Moderator: Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

  • Topic 3: miRNA as Cancer Biomarkers and Related Issues

    Moderator: Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research, Pathology, Stony Brook University

  • Topic 4: miRNAs and Exosomes

    Moderator: John Chevillet, Ph.D., Principal Scientist, N-of-One



NGS의 문제

8:25 의장 발언

Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

8:30 차세대 시퀀싱(NGS)을 이용한 인체병리학에서의 새로운 혈액 감염성 마이크로RNA 발견

Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

Although over 2,500 mature human miRNAs are known there is still a race for novel markers. Screening of blood cell fractions using NGS is a reasonable approach for discovering such minimally-invasive disease markers. With NGS as a high-throughput technique, however, a significant number of false positive biomarker candidates is reported. We present a complete pipeline: efficient discovery of novel miRNAs, filtering of false positives, and validation. The performance of the novel pipeline is demonstrated using neurological diseases as well as lung cancer.

9:00 폐암 탐지를 위한 기관지 상피에서의 마이크로RNA 발현

Ana Brandusa Pavel, Ph.D., Researcher, Computational Biomedicine, Boston University School of Medicine

Using bronchial brushings from current and former smokers undergoing bronchoscopy for suspect lung cancer, we profiled microRNA expression via small RNAseq on the Illumina HiSeq 2000 platform. We found microRNA expression profiles significantly associated with lung cancer and that these microRNAs target mRNA whose expression was previously reported to be associated with lung cancer. Importantly, we show that integrating microRNA expression together with a gene-expression lung cancer biomarker increases performance.

9:30 스폰서 제공 프레젠테이션(연사 모집 중)

9:45 전시회장 휴식시간, 포스터 발표 관람


암 경로에서 마이크로RNA의 역할

10:25 의장 발언

Richard I. Gregory, Ph.D., Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School, Harvard Stem Cell Institute, The Stem Cell Program at Boston Children's Hospital

10:30 전이성 흑색종에서 마이크로RNA의 예측 및 기능면의 역할

Eva Hernando, Ph.D., Associate Professor and Vice Chair for Science, Department of Pathology; Co-Leader, Melanoma Program, NYU Langone Medical Center

Our laboratory has identified a miRNA signature in primary melanomas predictive of recurrence and metastasis. We have also demonstrated that some components of that signature which are lost in aggressive primary tumors act as metastasis suppressors. Our data supports that a miRNA-based prognostic assay could identify patients at higher risk of developing metastatic disease who could be subjected to increased surveillance or adjuvant therapies. Moreover our results support that miRNA changes can capture the molecular heterogeneity that dictates metastatic behavior since early tumor stages.

11:00 암의 마이크로RNA 생합성 경로

Richard I. Gregory, Ph.D., Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School, Harvard Stem Cell Institute, The Stem Cell Program at Boston Children's Hospital

Amplification and overexpression of individual 'oncomiRs' or genetic loss of tumor suppressor miRNAs promotes tumorigenesis. Furthermore, global miRNA depletion caused by genetic and epigenetic alterations in components of the miRNA biogenesis machinery is oncogenic. This, together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer.

11:30 Smad2와 자식작용을 통한 miR-140에 의한 대장암 줄기세포 제거

Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research, Pathology, Stony Brook University

Colorectal cancer (CRC) is the third highest mortality cancer in the US and frequently metastasizes to liver and lung. Smad2 is a key element downstream of the TGF-β signaling pathway to regulate cancer metastasis by promoting epithelial to mesenchymal transition and maintaining the cancer stem cell (CSC) phenotype. In this study, we show that hsa-miR-140-5p directly targets Smad2 and overexpression of hsa-miR-140-5p in CRC cell lines decreases Smad2 expression levels, leading to decreased cell invasion and proliferation, and increasing cell cycle arrest. The functional and clinical significance of hsa-miR-140-5p suggests that it is a key regulator in CRC progression and metastasis, and may have potential as a novel therapeutic molecule to treat CRC.

12:00 컨퍼런스 폐막



첫째날 | 둘째날

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.


Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English


View Media Partners


Catalog

 

국제컨퍼런스
Gii Event
이벤트 캘린더
의약품 관련 국제컨퍼런스
메일링 서비스
메일링 서비스

CHI | Cambridge HealthTech Institute
한국어 공식사이트 운영 : Cambridge HealthTech Institute 파트너 (주)글로벌인포메이션